HOME >> BIOLOGY >> NEWS
Small subset of cells has big role in controlling immunity, study finds

A small subset of cells that tells the immune system whether to attack may be a future target for therapies to help patients fight tumors and keep transplanted organs, a Medical College of Georgia researcher says.

Dendritic cells roam the body, picking up invaders, such as a virus or cancer, then show their finds to the T-cells and tell them how to respond, says Dr. Andrew L. Mellor, molecular geneticist and immunologist and director of the MCG Immunotherapy Center.

Work published in the Aug. 15 issue of The Journal of Immunology by Dr. Mellor and his colleagues gives further clues over what direction dendritic cells will give.

They have shown that giving mice an experimental immunosuppressive agent causes a select number of these cells to express an enzyme, indoleamine 2,3 dioxygenase, or IDO, and that those cells tell T-cells not to respond.

"They are a very fascinating new subset of dendritic cells previously not recognized," says Dr. Mellor, Georgia Research Alliance Eminent Scholar in Molecular Immunogenetics. "We do not think all dendritic cells have the capacity to express IDO. The magic of this subset is their ability to do that," he said of the enzyme first identified for its role in helping a fetus escape rejection by the mother's immune system.

"One of the things we argue in this paper is that we can use IDO to help us find out if dendritic cells are going to stimulate the immune system or turn it off. If they express IDO, they will not stimulate T cells to respond. If they don't express IDO, they are likely to stimulate immune responses once they mature," Dr. Mellor says.

Five years ago nearly to the day, Dr. Mellor and his colleagues, Drs. David Munn and Simon Conway, were reporting in the journal Science that the developing fetus uses IDO to locally disable the mother's immune system. It works by degrading tryptophan, an amino acid critical to the survival of T-cells, which get their action cues from d
'"/>

Contact: Toni Baker
tbaker@mail.mcg.edu
706-721-4421
Medical College of Georgia
15-Aug-2003


Page: 1 2 3 4

Related biology news :

1. Small, Smac-like molecule encourages death of cancer cells
2. Small animal imaging gives cancer clues
3. Small RNA surmounts large cancer problem
4. Small, cold, & hungry: Ultra-small microbes from 120,000-year-old glacier ice sample
5. Small trial shows daclizumab add-on therapy improves MS outcome
6. Small gene changes in some leukemia patients may explain varying responses to chemotherapy
7. Small amounts of alcohol or anesthetics may damage the developing brain
8. Smallpox in 50-year-old tissues detected by integrated diagnostics approach
9. Small-molecule inhibitors of anthrax lethal factor identified
10. Smallpox in Europe selected for genetic mutation that confers resistance to HIV infection
11. Small-molecule inhibitors of botulinum neurotoxin identified

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Small subset cells has big role controlling immunity study finds

(Date:6/18/2015)... 18, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market announces that its Wocket® smart ... "Money on the Mark", scheduled to air on WABC Radio ... 20 th . The broadcast air- time ... to 8:00pm EST. NXT-ID, Inc.,s CEO Gino Pereira ...
(Date:6/17/2015)... GARDENS, Fla. , June 17, 2015 /PRNewswire/ ... solutions, today announced that its U.are.U ® ... Togo,s Eateries, Inc., a ... casual sandwich chain, to increase security, improve accountability ... fingerprint readers enable instant, non-repudiable identity confirmation for ...
(Date:6/16/2015)... Sweden , June 16, 2015 ... from previously communicated that it will amount to at least ... MSEK. Due to the rapid increase in market growth and ... the previously communicated guidance that revenue for 2015 will exceed ... will amount to approximately 2,200 MSEK. Due to ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3
(Date:6/30/2015)... BOSTON , June 30, 2015  Juniper ... company focused on developing therapeutics that address unmet ... CFO George Elston will present at ... , Wednesday, July 8, 2015Time: , 4:45 PM ... NYWebcast (live & archive): , www.juniperpharma.com, under  ...
(Date:6/30/2015)... ... June 30, 2015 , ... With its latest polyacrylonitrile ... to achieve faster flow rates in comparison to nylon or polyethersulfone (PES). ... to allow easy liquid flow while trapping particulates as small as 0.2 micron ...
(Date:6/30/2015)... , ... June 30, 2015 , ... Matrix Marketing ... that it has hired Gem Swartz to head up its account management department as ... director. Both Gem and Amanda bring senior account management and delivery expertise to the ...
(Date:6/30/2015)... , June 30, 2015 /PRNewswire/ - RepliCel Life ... stage regenerative medicine company focused on the development ... participant in its Phase 1/2 clinical trial of ... unilateral Achilles tendinosis, has been enrolled and their ... ultrasound-guided injections. RCT-01 is comprised of non-bulbar dermal ...
Breaking Biology Technology:Juniper Pharmaceuticals to Present at Cantor Fitzgerald Inaugural Healthcare Conference on July 8, 2015 2New Nanofiber Membrane Provides Fast, Efficient Filtration 2Matrix Marketing Group Expands Client Services Team 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 3RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 4
Cached News: